LINK"One of the strongest predictors of mortality and morbidity in ICH patients is hematoma volume and with the administration of NovoSeven hematoma growth was significantly limited," said Dr. Stephan Mayer, associate professor and director, Neurological Intensive Care Unit, Columbia University Medical Center and lead investigator of the study. "The current medical and surgical treatment options for ICH are not effective. Thirty-five to fifty percent of patients die within one month and if they survive, they are living with serious neurological deficits. The current data suggest a possible change in our paradigm for the treatment of ICH."